{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=85", "query": { "intervention": "placebo", "page": 85 }, "page_size": 10 }, "pagination": { "page": 85, "page_size": 10, "total_count": 33121, "total_pages": 3313, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=86&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo&page=84&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-01T16:46:50.925Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05610280", "title": "A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertriglyceridemia", "Cardiovascular Diseases", "Atherosclerosis" ], "interventions": [ { "name": "Olezarsen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1478, "start_date": "2022-11-21", "completion_date": "2025-06-09", "has_results": false, "last_update_posted_date": "2026-02-10", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Beverly Hills, California + 54 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05610280" }, { "nct_id": "NCT06954662", "title": "A Targeted Amino Acid Supplement for People With Parkinson's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Parkinson Disease, Idiopathic" ], "interventions": [ { "name": "Amino acid supplement", "type": "DRUG" }, { "name": "Whey Protein Supplement", "type": "DIETARY_SUPPLEMENT" }, { "name": "Isonitrogenous Placebo Supplement", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "UConn Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 3, "start_date": "2025-05-22", "completion_date": "2025-07-17", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 1, "location_summary": "Farmington, Connecticut", "locations": [ { "city": "Farmington", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06954662" }, { "nct_id": "NCT01542788", "title": "Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "SOF", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "Placebo to match SOF", "type": "DRUG" }, { "name": "Placebo to match RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 278, "start_date": "2012-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-05-19", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 50, "location_summary": "Birmingham, Alabama • Coronado, California • Los Angeles, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01542788" }, { "nct_id": "NCT01663727", "title": "Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Bevacizumab [Avastin]", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 481, "start_date": "2012-08-27", "completion_date": "2017-11-21", "has_results": true, "last_update_posted_date": "2019-01-22", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Corona", "state": "California" }, { "city": "Glendora", "state": "California" }, { "city": "La Verne", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663727" }, { "nct_id": "NCT05195918", "title": "Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "EGCG 300 mg + Nintedanib", "type": "COMBINATION_PRODUCT" }, { "name": "EGCG 300 mg + Pirfenidone", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo 2 capsules + Nintedanib or Pirfenidone", "type": "COMBINATION_PRODUCT" }, { "name": "EGCG 600 mg + Nintedanib", "type": "COMBINATION_PRODUCT" }, { "name": "EGCG 600 mg + Pirfenidone", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo 4 capsules + Nintedanib or Pirfenidone", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Hal Chapman", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 50, "start_date": "2023-08-24", "completion_date": "2026-03-19", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 7, "location_summary": "San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05195918" }, { "nct_id": "NCT02212990", "title": "The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Fever" ], "interventions": [ { "name": "Acetaminophen Arm", "type": "OTHER" }, { "name": "Placebo Arm", "type": "OTHER" }, { "name": "Ibuprofen Arm", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "47 Months", "sex": "ALL", "summary": "6 Months to 47 Months" }, "enrollment_count": 104, "start_date": "2014-09", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2018-02-07", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02212990" }, { "nct_id": "NCT03120520", "title": "An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Idiopathic Constipation" ], "interventions": [ { "name": "Plecanatide", "type": "DRUG" }, { "name": "Matching placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bausch Health Americas, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 124, "start_date": "2017-01", "completion_date": "2018-09-07", "has_results": true, "last_update_posted_date": "2019-10-04", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 36, "location_summary": "Foley, Alabama • Jonesboro, Arkansas • Cerritos, California + 33 more", "locations": [ { "city": "Foley", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Corona", "state": "California" }, { "city": "Downey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03120520" }, { "nct_id": "NCT04740580", "title": "Glutathione, Brain Metabolism and Inflammation in Alzheimer's Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Glycine", "type": "DIETARY_SUPPLEMENT" }, { "name": "N-acetylcysteine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Alanine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "55 Years to 85 Years" }, "enrollment_count": 52, "start_date": "2022-02-15", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04740580" }, { "nct_id": "NCT00809159", "title": "Double Blind, Placebo Controlled Study to Assess Efficacy of AIN457 in Moderate to Severe Ankylosing Spondylitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ankylosing Spondylitis" ], "interventions": [ { "name": "AIN457", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 60, "start_date": "2009-03", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-12-09", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 10, "location_summary": "Paradise Valley, Arizona • Springfield, Illinois • Oklahoma City, Oklahoma + 6 more", "locations": [ { "city": "Paradise Valley", "state": "Arizona" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Springfield", "state": "Illinois" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Duncansville", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00809159" }, { "nct_id": "NCT05427279", "title": "Effects of Vitamin C Enriched Hydrolyzed Collagen, PrimaColl™, Whey Protein, or Placebo on Collagen Synthesis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Effect of Food Supplement" ], "interventions": [ { "name": "Placebo", "type": "DIETARY_SUPPLEMENT" }, { "name": "Hydrolized Collagen", "type": "DIETARY_SUPPLEMENT" }, { "name": "PrimaColl", "type": "DIETARY_SUPPLEMENT" }, { "name": "Whey protein", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "University of California, Davis", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "18 Years to 30 Years" }, "enrollment_count": 20, "start_date": "2022-10-05", "completion_date": "2024-09-30", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-11-01T16:46:50.925Z", "location_count": 1, "location_summary": "Davis, California", "locations": [ { "city": "Davis", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05427279" } ] }